My research objectives centre on new technology development for improving diagnostics and therapeutics applied to skin. I have developed and patented novel devices for minimally invasive topical drug delivery and skin sampling. My leadership and tangible research outcomes are now enabling previously impossible skin research to be done and now are also impacting the commercial sector in addition to creating new knowledge in the field.
Strengthening Primary Health Care Systems For Under-served Populations Worldwide
Funder
National Health and Medical Research Council
Funding Amount
$476,728.00
Summary
The World Health Organization has identified the strengthening of primary health care systems as a priority area for global health. My research program focusses on identifying, developing and testing innovative strategies to improve access to high quality primary health care for under-served populations in Australia (particularly for Aboriginal and Torres Strait Islander communities), rural India, China and the USA.
Discovering The Genetic Causes Of Congenital Heart Disease Using Systems Biology
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Congenital heart disease (CHD) affects one in one hundred live-born babies, representing a significant health burden in Australia and worldwide. My research team is using state-of-the-art DNA sequencing technology to sequence the entire genome of hundreds of patients with CHD and their family members. My research program develops fast and reliable computer software to accelerate the discovery of the genetic causes of CHD, and make personalised genome-based medicine a reality.
Novel Health Data Systems For Translation And Impact
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Health research seeks to benefit society by improving health. However, there is a gap between the findings of research and healthcare practice. New systems are beginning to change the way research data are used to improve health outcomes. I am an HIV specialist developing and evaluating several new data systems and my vision for the next four years is to use these to improve the translation of health research into practice and policy for the benefit of people with HIV and society at large.
Exploring And Exploiting Novel Therapeutic Avenues In Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Mesothelioma is a fatal cancer of the lungs. It rapidly grows and invades surrounding tissues such as the ribcage, causing severe shortness of breath and pain. Chemotherapy has limited effect and although immunotherapy appears promising, most patients do not respond. I will investigate why mesothelioma is so invasive; how to improve the response to immunotherapy and how to best combine chemotherapy and immunotherapy. I aim to develop new treatments that will benefit patients with mesothelioma.
Platform Nanotechnologies For Oral Delivery Of Drugs, Therapeutic Protein And Peptide Delivery
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
The development of reliable oral delivery systems for problem drugs and biologics is one of the biggest challenges faced by the pharmaceutical industry in recent times. In order to tackle these challenges, I have developed programmable nanoparticles capable of efficiently deliver wide range of drugs including large peptides and proteins orally.
NEW INSIGHTS IN TREATMENT AND DIAGNOSIS OF GLAUCOMA
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Effective treatment of glaucoma and understanding the exact mechanism of cell death in glaucoma still remain challenging. Here I utilize a smart nanoparticle that could recognize sick cells followed by releasing drugs only to cells that are stressed and need the drug. High-resolution microscopy can map the detailed activity in retina after drug treatments. By doing so, we develop a novel way to deliver drugs to diagnose and treat glaucoma.
New medicines are urgently needed for infectious diseases due to widespread resistance to many traditional antibiotics. This research will develop and apply state-of-the-art techniques to measure metabolism in parasites and bacteria, and reveal how drugs inhibit metabolic pathways in these microorganisms. This will provide important information about how current drugs work, and assist with the development of new medicines for infectious diseases.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Distinguishing Self From World: Understanding The Neural Basis Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$453,307.00
Summary
Self-generated sensations - such as tickling oneself - typically evoke less activity in the EEG than physically identical, externally-produced sensations. Schizophrenia patients do not exhibit this “electrophysiological self-suppression” (ESS), which accounts for their characteristic tendency to misattribute their own thoughts and actions to other people. This project aims to rectify ESS levels in schizophrenia by artificially altering patients’ sensory feedback to self-generated actions.